Digital RESI November Panel Spotlight on Early-Stage Therapeutics

5 Nov

By Joey Wong, Investor Research Analyst, LSN

The Digital RESI November Conference is less than 2 weeks away! Digital RESI is the premier partnering conference experience for the early-stage entrepreneur and their strategic partners, featuring a match-based partnering platform in addition to educational and insightful content, such as workshops, pitch sessions, and live investor panels spanning the sectors of drugs, devices, diagnostics, and digital health.

The Early Stage Therapeutics Investors panel will feature five investors with extensive experience in early-stage therapeutics to discuss their investment mandates and how their own investment process works.

Fundraising executives developing therapeutic assets will get an insightful look at the strategies used by early-stage therapeutic investors to assess companies at the earliest, riskiest stage of development. They can learn to position their companies as an attractive investment opportunity under the current investment landscape. The live session will feature:

Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels (Moderator)

Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships.Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group. He is president of Blue Cactus Consulting (bluecactusconsulting.com), and CEO of Native State Therapeutics, a recently-formed biotechnology company, in the neurodegenerative space.

Sascha Berger, Partner, TVM Capital Life Science

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund. Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea). During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Sunil Shah, CEO, O2h Ventures

Sunil has been active in the early stage biotech community in the UK since the mid 1990’s, his respective thesis at Cambridge addressed issues in virtualised networks in science. In 2003, following a brief period at PA Consulting Group Oxygen Healthcare was formed providing discovery services to biotech and pharma. The company grew into a team of 350 employees and was acquired by Piramal Enterprises (NSE:PEL) in 2011-2013. o2h Ventures was co-founded by Sunil in 2013. In the last 4 years, it has co-founded four companies with UK based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early stage investments, and executed early stage drug discovery research projects for fifteen different companies.

Travis Whitfill, Partner, Bios Partners

Travis Whitfill is a Partner at Bios Partners. His background began in molecular biology and biochemistry at the MD Anderson Cancer Center and Duke University. He is the co-founder of several startup companies. He is on the board of several companies, including Incysus Therapeutics. He brings a strong background in entrepreneurship and business and was acknowledged as Forbes’ 30 Under 30 in 2018. He’s also the Senior Analyst at Bios Research. He also is an Associate Research Scientist in the Departments of Pediatrics and Emergency Medicine at Yale. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 40 publications. Mr. Whitfill received degrees from Yale University (MPH) and Dallas Baptist University (BS) and is working on a PhD from University College London.

Z Haroon, Chairman and General Partner, Julz Co LLC

Julz Co is an investment management company focused on investing in early-stage healthcare companies in the area of therapeutics, medical devices, services and digital healthcare. The company has offices in Chapel Hill, North Carolina, USA and Suzhou, China. Julz invests globally in companies that have novel and proprietary technology addressing a vital market need and are driven by experienced management teams.

Partnering at RESI is open! But there is still time to register to participate and join these investors at the next Digital RESI, November 17 -19. Don’t miss out on the many elements that make Digital RESI the leader in the early-stage deal-making ecosystem.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: